Malaysia Nuclear Medicines Market Current Trends and Future Scenarios $70.24 million by 2028

Malaysia Nuclear Medicines Market generated $33.68 million in 2020, and is expected to reach $70.24 million by 2028, growing at a CAGR of 9.9% from 2020-2028.

WILMINGTON, DELAWARE, UNITED STATES, July 11, 2024 /EINPresswire.com/ -- According to Allied Market Research Malaysia Nuclear Medicines Market Reoprt generated $33.68 million in 2020, and is expected to reach $70.24 million by 2028, growing at a CAGR of 9.9% from 2020-2028. The diagnostic application segment dominated the market in 2020, contributing to more than 90% of the total revenue. However, the therapy treatment segment is projected to register the highest CAGR of 17.0% during the forecast period.

𝐋𝐢𝐬𝐭 𝐨𝐟 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 :

The Malaysia nuclear medicines market report includes an in-depth analysis of the prime market players such as Fujifilm Holdings Corporation (Irvine Scientific Sales Company, Inc.), Cardinal Health, Inc., Ion Beam Applications (Ion Beam Applications, SA), GE Healthcare, MERCK KGAA (Sigma Aldrich), Lantheus Holdings, Inc. (Lantheus Medical Imaging, Inc.), Otsuka Holding Co., Ltd. (ABX advanced biochemical compounds GmbH), Novartis AG (Advanced Accelerator Applications S.A.), Siemens Healthcare GmbH, and Taiyo Nippon Sanso Corporation (Mitsubishi Chemical Holdings Corp).

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://www.alliedmarketresearch.com/request-sample/11880

𝗖𝗼𝘃𝗶𝗱-𝟭𝟵 𝗦𝗰𝗲𝗻𝗮𝗿𝗶𝗼:

• The pandemic led to decrease in the number of diagnostic and therapeutic procedures with nuclear medicines, as Covid-19 is a communicable disease.
• Several countries imposed country-wide lockdown to curb the spread of infection. During the lockdown, the number of patient visits to hospitals and clinics dropped significantly.
• On the other hand, radiopharmaceuticals could help in the detection of the coronavirus. Moreover, it can provide evidence and clarify contradictory concepts in use of non-steroidal and anti-inflammatory drugs for Covid-19.

𝐅𝐨𝐫 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲 https://www.alliedmarketresearch.com/purchase-enquiry/11880

Rise in incidence of targeted population in Malaysia, surge in adoption of SPECT and PET scans, and increase in geriatric population in Malaysia drive the growth of the Malaysia nuclear medicines market. However, short half-life of radiopharmaceuticals coupled with supply volatility, logistical challenges, and stringent regulatory policies in Malaysia hinders the market. On the contrary, use of radiopharmaceuticals in neurological applications is expected to open lucrative opportunities for the market players in the future.

On the basis of modality, the brachy therapy segment is estimated to manifest the highest CAGR of 18.5% from 2020 to 2028. However, the SPECT segment held the lion’s share in 2020, accounting for around three-fifths of the market.

Based on end users, the research institutes segment is anticipated to manifest the highest CAGR of 13.0% during the forecast period. However, the hospitals and diagnostic centers segment held the largest share in 2020, contributing to around 90% of the Malaysia nuclear medicines market.

𝗚𝗲𝘁 𝗗𝗲𝘁𝗮𝗶𝗹𝗲𝗱 𝐑𝐞𝐩𝐨𝐫𝐭 https://www.alliedmarketresearch.com/malaysia-nuclear-medicines-market-A11515

𝐑𝐞𝐥𝐚𝐭𝐞𝐝 𝐑𝐞𝐩𝐨𝐫𝐭𝐬:

Cardiovascular Diagnostic Testing Market

Meningitis imaging Market

𝐀𝐕𝐄𝐍𝐔𝐄- 𝐀 𝐒𝐮𝐛𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧-𝐁𝐚𝐬𝐞𝐝 𝐋𝐢𝐛𝐫𝐚𝐫𝐲 (𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐨𝐧-𝐝𝐞𝐦𝐚𝐧𝐝, 𝐬𝐮𝐛𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧-𝐛𝐚𝐬𝐞𝐝 𝐩𝐫𝐢𝐜𝐢𝐧𝐠 𝐦𝐨𝐝𝐞𝐥) 𝐎𝐟𝐟𝐞𝐫𝐞𝐝 𝐛𝐲 𝐀𝐥𝐥𝐢𝐞𝐝 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡:

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

𝐆𝐞𝐭 𝐚𝐧 𝐚𝐜𝐜𝐞𝐬𝐬 𝐭𝐨 𝐭𝐡𝐞 𝐥𝐢𝐛𝐫𝐚𝐫𝐲 𝐨𝐟 𝐫𝐞𝐩𝐨𝐫𝐭𝐬 𝐚𝐭 𝐚𝐧𝐲 𝐭𝐢𝐦𝐞 𝐟𝐫𝐨𝐦 𝐚𝐧𝐲 𝐝𝐞𝐯𝐢𝐜𝐞 𝐚𝐧𝐝 𝐚𝐧𝐲𝐰𝐡𝐞𝐫𝐞. 𝐅𝐨𝐫 𝐦𝐨𝐫𝐞 𝐝𝐞𝐭𝐚𝐢𝐥𝐬, 𝐟𝐨𝐥𝐥𝐨𝐰 𝐭𝐡𝐞 𝐥𝐢𝐧𝐤: https://www.alliedmarketresearch.com/library-access

𝐀𝐛𝐨𝐮𝐭 𝐀𝐥𝐥𝐢𝐞𝐝 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of the domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Market Research
email us here
+1 800-792-5285
Visit us on social media:
Facebook
X